The AHR–NRF2–JDP2 gene battery: Ligand–induced AHR transcriptional activation

IF 5.6 2区 医学 Q1 PHARMACOLOGY & PHARMACY Biochemical pharmacology Pub Date : 2025-01-23 DOI:10.1016/j.bcp.2025.116761
Kenly Wuputra , Wen-Hung Hsu , Chia-Chen Ku , Ya-Han Yang , Kung-Kai Kuo , Fang-Jung Yu , Hsin-Su Yu , Kyosuke Nagata , Deng-Chyang Wu , Chao-Hung Kuo , Kazunari K. Yokoyama
{"title":"The AHR–NRF2–JDP2 gene battery: Ligand–induced AHR transcriptional activation","authors":"Kenly Wuputra ,&nbsp;Wen-Hung Hsu ,&nbsp;Chia-Chen Ku ,&nbsp;Ya-Han Yang ,&nbsp;Kung-Kai Kuo ,&nbsp;Fang-Jung Yu ,&nbsp;Hsin-Su Yu ,&nbsp;Kyosuke Nagata ,&nbsp;Deng-Chyang Wu ,&nbsp;Chao-Hung Kuo ,&nbsp;Kazunari K. Yokoyama","doi":"10.1016/j.bcp.2025.116761","DOIUrl":null,"url":null,"abstract":"<div><div>Aryl hydrocarbon receptor (AHR) and nuclear factor-erythroid 2-related factor 2 (NRF2) can regulate a series of genes encoding the detoxifying phase I and II enzymes, via a signaling crosstalk known as the “AHR–NRF2 gene battery”. The chromatin transcriptional regulator Jun dimerization protein 2 (JDP2) plays a central role in the<!--> <!-->transcription of <em>AHR</em> gene in response to the phase I enzyme ligand 2,3,7,8-tetrachlorodibenzo-<em>p</em>-dioxin. It forms a transcriptional complex with AHR–AHR nuclear translocator (ARNT) and NRF2-small musculoaponeurotic fibrosarcoma proteins (sMAF), which are then recruited to the respective <em>cis</em>-elements, such as dioxin response elements and antioxidant response elements, respectively, in the AHR promoter. Here, we present a revised description of the AHR–NRF2 gene battery as the AHR–NRF2–JDP2 gene battery for transactivating the AHR promoter by phase I enzyme ligands. The chromatin regulator JDP2 was found to be involved in the movement of AHR–NRF2 complexes from the dioxin response element to the antioxidant response element in the AHR promoter, during its activation in a spatiotemporal manner. This new epigenetic and chromatin remodeling role of AHR–NRF2–JDP2 axis is useful for identifying new therapeutic targets for various diseases, including immunological response, detoxification, development, and cancer-related diseases.</div></div>","PeriodicalId":8806,"journal":{"name":"Biochemical pharmacology","volume":"233 ","pages":"Article 116761"},"PeriodicalIF":5.6000,"publicationDate":"2025-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemical pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0006295225000231","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Aryl hydrocarbon receptor (AHR) and nuclear factor-erythroid 2-related factor 2 (NRF2) can regulate a series of genes encoding the detoxifying phase I and II enzymes, via a signaling crosstalk known as the “AHR–NRF2 gene battery”. The chromatin transcriptional regulator Jun dimerization protein 2 (JDP2) plays a central role in the transcription of AHR gene in response to the phase I enzyme ligand 2,3,7,8-tetrachlorodibenzo-p-dioxin. It forms a transcriptional complex with AHR–AHR nuclear translocator (ARNT) and NRF2-small musculoaponeurotic fibrosarcoma proteins (sMAF), which are then recruited to the respective cis-elements, such as dioxin response elements and antioxidant response elements, respectively, in the AHR promoter. Here, we present a revised description of the AHR–NRF2 gene battery as the AHR–NRF2–JDP2 gene battery for transactivating the AHR promoter by phase I enzyme ligands. The chromatin regulator JDP2 was found to be involved in the movement of AHR–NRF2 complexes from the dioxin response element to the antioxidant response element in the AHR promoter, during its activation in a spatiotemporal manner. This new epigenetic and chromatin remodeling role of AHR–NRF2–JDP2 axis is useful for identifying new therapeutic targets for various diseases, including immunological response, detoxification, development, and cancer-related diseases.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
AHR- nrf2 - jdp2基因电池:配体诱导的AHR转录激活。
芳烃受体(AHR)和核因子-红细胞2相关因子2 (NRF2)可以通过“AHR-NRF2基因电池”信号串扰调控一系列编码解毒I期和II期酶的基因。染色质转录调控因子Jun二聚化蛋白2 (JDP2)在AHR基因响应I期酶配体2,3,7,8-四氯二苯并-对二恶英的转录中起核心作用。它与AHR-AHR核转位子(ARNT)和nrf2 -小肌腱神经纤维肉瘤蛋白(sMAF)形成转录复合体,然后被募集到各自的顺式元件上,如AHR启动子中的二恶英反应元件和抗氧化反应元件。在这里,我们提出了AHR- nrf2基因电池的修订描述为AHR- nrf2 - jdp2基因电池,通过I相酶配体反激活AHR启动子。研究发现,在AHR启动子的激活过程中,染色质调节因子JDP2参与了AHR- nrf2复合物从二恶英反应元件到抗氧化反应元件的时空运动。AHR-NRF2-JDP2轴的这种新的表观遗传和染色质重塑作用有助于确定各种疾病的新治疗靶点,包括免疫应答、解毒、发育和癌症相关疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Biochemical pharmacology
Biochemical pharmacology 医学-药学
CiteScore
10.30
自引率
1.70%
发文量
420
审稿时长
17 days
期刊介绍: Biochemical Pharmacology publishes original research findings, Commentaries and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics. The journal''s target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process. All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complimentary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review. While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.
期刊最新文献
Sarcopenia: An overview of emerging therapies and pathophysiological insights in age-related skeletal muscle decline. USP5 stabilizes FoxM1 to enhance trophoblast proliferation, invasion and migration in recurrent spontaneous abortion. Illuminating chromaffin granules: compartmentalization of endocannabinoids in bovine adrenal glands supports role in hormone modulation. Suppression of hepatic PPARα by hypoxia disrupts cholesterol metabolism and indirectly impairs arterial endothelial function in MASLD. From 2020 to 2025: Comprehensive review Decoding novel structural inhibitors for Mpro of SARS-CoV-2.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1